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ABSTRACT

Streptococcus pneumoniae is a bacterial pathogen that continues to be a major
cause of disease around the world. It is not only the number one cause of bacterial
pneumonia but also the cause of about 15% of the deaths of children under 5 around the
world. There is a lot of research done on this organism, but with around 100 known
serotypes and each one producing a unique capsule, there is still much more to be
studied. The Etiology of Pneumonia in the Community (EPIC) study conducted by the
CDC observed the burden of hospitalizations caused by pneumonia while determining the
organism responsible. One of the most common organisms isolated from both children
and adult patients was S. pneumoniae. To look further into these clinical isolates, we
chose three different type 3 pneumococcal isolates and observed the immune cellular
dynamics as well as capsule production, and saw that even with the same serotype
immune responses can differ.
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CHAPTER 1.

INTRODUCTION

Burden of Streptococcus pneumoniae
Millions of people in the United States are affected by respiratory diseases
annually. Included in these and one of the most prevalent is pneumococcal disease caused
by Streptococcus pneumoniae [1]. S. pneumoniae is a Gram-positive, facultative
anaerobic bacterium found in the nasal passage of the majority of the population. This
bacterium can have a commensal relationship with the host meaning it can be an
opportunistic pathogen. Once an individual is infected with S. pneumoniae in their upper
respiratory tract, it can spread to the lungs, the membranes surrounding the brain and
spinal cord, the blood, and the middle ear resulting in pneumococcal disease.
Pneumococcal disease can include community-acquired bacterial pneumonia, meningitis,
bacteremia, and acute otitis media respectively. S. pneumoniae is known as the leading
cause of community-acquired bacterial pneumonia and causes around 150,000
hospitalizations each year [2]. The financial burden from pneumococcal hospitalizations
is a growing problem in the U.S. as well as across the world with the increasing problem
of antibiotic resistance [3,4]. The WHO has also estimated that pneumonia causes about
15% of the death of children under 5 worldwide; with S. pneumoniae being the most
common cause of bacterial pneumonia [1]. Transmission and disease progression must
be understood for this bacterium to aid in preventing the spread and reducing the public
health burden of this disease.

Streptococcus pneumoniae Transmission
The transmission of commensal respiratory organisms, specifically S. pneumoniae
requires encountering respiratory secretions either through direct inhalation of these
droplets or through contact with a contaminated surface, while self-inoculation is also
possible when a person is a carrier of the bacteria in their upper respiratory tract.
Transmission of the disease seems to occur more frequently during the colder months due
to more frequent infections of other respiratory diseases as well as more frequent
crowding in smaller spaces, but other factors seem to predispose a person to contract
pneumococcal disease [5]. These factors include but are not limited to a decreased
immune response and function, chronic diseases such as asthma, smoking, alcoholism, or
cochlear implants [6].

Polysaccharide Capsule
There are around 100 known serotypes of Streptococcus with not all causing
disease. Each serotype produces its own unique capsule, which is comprised of
polysaccharides. The capsule plays an important role in the evasion of the host immune
system, as well as virulence for the organism [7]. Most serotypes have a capsule that is
negatively charged which helps with the evasion of the host’s defenses. Upon initial
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colonization of pathogens in the nasal passage, mucus is one of the host’s first lines of
defense. Mucus is comprised of mostly mucopolysaccharides, which are negatively
charged partly because of the sialic acid. Due to this negative charge of the mucus as well
as the negative charge of the capsule, there are repelling forces allowing for the escape of
pneumococcus [7,8]. Another mechanism for S. pneumoniae to evade the host’s immune
system is by escaping from phagocytosis from neutrophils and the neutrophil
extracellular traps (NETs) they produce [9].
Depending on the serotype of S. pneumoniae, the biosynthesis of the capsular
polysaccharide can occur through either the synthase-dependent mechanism or the Wzydependent pathway. The synthase-dependent pathway is used by types 3 and 37, while
the Wzy-dependent pathway is used by all other known types [10]. Serotype 3 uses the
Cps3S synthase to initiate synthesis by transferring glucose to a phosphatidylglycerol
acceptor and continues the process to extend the polysaccharide [11]. This synthasedependent mechanism results in the capsule polysaccharide not being covalently linked to
the cell wall, unlike other serotypes that use the Wzy-dependent mechanism.
This difference in the biosynthesis of the capsular polysaccharide plays an
important role in the effectiveness of the pneumococcal vaccine against S. pneumoniae
[12]. There are two pneumococcal vaccines in use today, the pneumococcal conjugate
vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23) [20]. S.
pneumoniae serotype 3 is included in both vaccines, yet it continues to be a major cause
of invasive pneumococcal disease [21]. A study by Choi et al., showed the failure in
efficacy against pneumococcus type 3 is in part due to the capsular polysaccharide not
being covalently linked to the cell wall. If there are anti-CPS antibodies bound to the
organism, S. pneumoniae type 3 can release its capsule and prevent the antibodydependent killing of the organism [12]. With only serotypes 3 and 37 using this synthasedependent mechanism, and type 37 not seen often in human patients [12], it is vital that
more is understood about serotype 3 and the diseases it can cause.

EPIC Study
In January 2010, the CDC began the Etiology of Pneumonia in the Community
(EPIC) study which tried to determine what the burden of hospitalizations due to
pneumonia was in children and adults as well as determine which viruses and bacteria
were associated with these hospitalizations. There were eight hospitals enrolled in this
study with three being pediatric hospitals and five being adult hospitals. Specimens such
as blood, urine, nasopharyngeal, pleural fluid, and sputum were collected to test for
different bacterial organisms or viral particles. One of the most common pathogens
detected in the samples collected was S. pneumoniae in 5% of the adult patients and 4%
of the children; of these isolates collected several of them were serotype 3 pneumococcus
[13,14]. Three of these serotype 3 strains were chosen to determine the host’s immune
cell dynamics as well as the lung and blood bacterial burdens due to the complications
that can occur with this serotype, as well as to determine any differences that may occur
within the same serotype of S. pneumoniae that have been isolated from different
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environments. These isolates are labeled as P110585, P210828, P310795 and were
isolated from a sputum sample of a 56-year-old patient, a sputum sample of a 23-monthold patient, and a pleural fluid sample from a 22-month-old patient respectively. Each of
these patients was virally coinfected at the time of isolation as well. P110585 was
coinfected with parainfluenza virus type 3 (PIV3), P210828 was coinfected with
influenza B, and P310795 was coinfected with respiratory syncytial virus (RSV). The lab
strain A66.1 was used as a known comparison.
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CHAPTER 2.

MATERIALS AND METHODS

Mice
Female BALB/c 6-8 week old mice were obtained from Charles River
Laboratories. Mice were housed in groups of five in 38.2 cm x 19.4 cm x 13.0 cm solidbottom polysulfone individually ventilated cages. Rooms for housing mice were
maintained on a 12:12-hour light: dark cycle at 22  2C with 50% humidity in the
biosafety level two facility at the University of Tennessee Health Science Center
Regional Biocontainment Center (Memphis, TN). Prior to inclusion in the experiments,
mice were allowed to acclimate to the animal facility for at least seven days. Envigo
irradiated rodent diet (#2918) and autoclaved water were available ad libitum. All
experiments were performed under an approved protocol and in accordance with the
guidelines set forth by the Animal Care and Use Committee at UTHSC.

Infection Experiments
All experiments were done using type 3 pneumococcal clinical isolates obtained
from hospitalized patients labeled either P110585, P210828, or P310795. The bacterial
doses were determined by previous LD50 experiments. The doses were chosen as a
uniformly lethal dose (referred to as “high”) and a 50 percent lethal dose (referred to as
LD50). Frozen stocks of the inoculum were diluted in sterile PBS and administered
intranasally to groups of 5 mice. Mice were lightly anesthetized with 2.5% inhaled
isoflurane (Baxter, Deerfield, IL) in a total volume of 100 L (50 L per nostril). Mice
were inoculated with a designated dose at day 0. Weight loss, appearance, and behavior
were monitored to assess illness and mortality. Mice were euthanized if they lost 30% of
their starting body weight or became septic based on appearance and behavior.

Lung and Blood Harvesting and Processing
Mice were euthanized by 33% isoflurane inhalation. Lungs were aseptically
harvested, washed in PBS, and digested with collagenase (1 mg/ml, Sigma C0130) and
physical homogenization against a 40 µm cell strainer for immunology. Lung digest
supernatants were used to determine bacterial titers; bacterial titers were also measured in
peripheral blood. This was achieved by plating either the lung supernatant or blood in
dilutions from neat to 10-6 on blood agar with 20% neomycin and incubating for 48 hours
at 37C. Following red blood cell lysis, lung cells were washed in staining buffer (PBS,
5mM EDTA, 10mM HEPES, and 0.5% bovine serum albumin), counted with trypan blue
exclusion using a Cell Countess System (Invitrogen, Grand Island, NY), and prepared for
flow cytometric analysis as described below.
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Flow Cytometry
Flow cytometry (ZE5 Cell Analyzer, Bio-Rad, Hercules, CA (UTHSC)) was
performed on the cell pellets after incubation with 200 ul of 1:200 Fc block at 4C for 20
minutes, followed by viability (Biolegend, Zombie Violet Fixable Viability Kit) and
surface marker staining with anti-mouse antibodies. For total neutrophil, macrophage,
CD4+ T cell, and CD8+ T cell quantification, antibodies Ly6G (1A8, PeCy7), F4/80
(BM8, PE), CD11c (N418, FITC), CD11b (M1/70, A700), CD3e (145-2C11, BV786),
CD4 (RM4-5, V500), CD8a (53-6.7, BV605), CD49b (DX5, APC-e780) were used. The
data were analyzed using FlowJo 10.8.0 (Tree Star, Ashland, OR). Data were cleaned
using the flowAI application followed by gating for viable cells from a forward
scatter/side scatter plot, singlet inclusion, and viability dye exclusion. Neutrophils
(Ly6Ghi), macrophage populations (CD11chiF4/80hi), more specific alveolar macrophages
(AM) (CD11chiF4/80hiCD11b-), inflammatory macrophages (iM)
(CD11chiF4/80hiCD11b+), CD4 T Cells (CD3+CD8-CD4+CD49b-), and CD8 T Cells
(CD3+CD8+CD4-CD49b-) were gated.

Capsule Quantification
Capsule quantification for each S. pneumoniae patient isolate (P110585, P210828,
P310795) as well as the type 3 laboratory strain A66.1 was measured using ELISA and
read at 405nm. Wells of a 96 well plate were coated in bacteria that had been grown to a
specified OD620 for there to be 1e6 bacteria per well and stored at 4C overnight. Plates
were incubated with a blocking buffer for 2 hours. Serially diluted anti-capsule type 3
rabbit serum was incubated on the bacterial cells for 1 hour at RT and washed using a
wash buffer. The plate was then incubated with an anti-rabbit IgG, washed, and finally
incubated with yellow ELISA substrate. The plates were read at OD405.

Statistical Analysis
Significant differences in lung and blood bacterial loads and immune cells were
determined using multiple Mann-Whitney tests on linear values to compare the means of
a group of data and determine how different they may be (GraphPad Prism 9.3.0). The P
values ≤0.05 were considered significant.
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CHAPTER 3.

RESULTS

Growth Dynamics
To begin understanding the characteristics of the chosen isolates, survival studies
were performed using varying doses of the bacterial strains. Balb/c mice were
intranasally infected with the chosen dose of the assigned S. pneumoniae isolate. The
mice were monitored for 8 days post-infection. The lethal dose 50% (LD50) for each
strain was determined when 50% of the survival groups succumbed to the infection and a
lethal dose was determined when all mice in the group succumbed to the infection. The
LD50 for P110585, P210828, and P310795 were determined to be 1e3, 1e4, and 1e4,
respectively, while the high (uniformly lethal) dose was determined to be 1e4, 1e5, and
1e5, respectively (Figure 3-1A). For each of the high doses, the mice lost weight at
similar rates with each losing approximately 16% if infected with P110585, 20% if
infected with P210828, and 18% if infected with P310795 (Figure 3-1B). There was
minimal weight loss observed for the LD50 of each isolate (Figure 3-1B).

Bacterial Burdens
To determine the bacterial burden of each clinical isolate throughout the infection
at differing doses, lung supernatants were plated on blood agar with 20% neomycin and
incubated at 37C for 48 hours. The mice that had been given the LD50 did not grow to
high titers in the lung and most mice were able to clear the infection by 48 hours
(Figure 3-2A). The bacterial burden in the lungs of the high dose infected animals was
high and most animals were unable to clear the infection with P210828 having the most
bacterial burden at 24 hours post bacterial infection, but mice were able to clear some of
the infection by 48 hours except for the lab strain A66.1 infected animals, which had
titers that grew by 48 hours (Figure 3-2B). The number of bacteria in the blood differed
for each strain and dose with most mice not having any bacteria in the blood for the LD50
except for P110585. This strain was able to invade the blood by 24 hours with even
higher titers at 48 hours (Figure 3-2C). The high doses of each strain had bacteria in the
blood with each being at similar titers at 24 hours, but both P110585 (P=0.007937) and
the lab strain A66.1 (P=0.015873, P=0.007937) grew to significantly higher titers as
compared to strains P210828 and P310795 by 48 hours (Figure 3-2D).

Immune Cell Dynamics
To observe the immune cells, flow cytometry was used by staining for cell surface
markers. The gating scheme is shown in Figure 3-3. All clinical isolates at the LD50 had
a slight increase in neutrophils by 48 hours. The high dose of the clinical isolates had a
significant increase in neutrophils by 24 hours for P210828 compared to P110585
(P=0.007937), which was not a significant difference between the LD50 and the high dose
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Figure 3-1. Survival and Weight Loss of Animals Infected with S. pneumoniae
Clinical Isolates
(A) Survival curves for both LD50 and high doses of all type 3 pneumococcal clinical
isolates. (B) Weight loss curves of both LD50 and high doses of all type 3 pneumococcal
clinical isolates.
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Figure 3-2.

Bacterial Burdens Differ with Strain and Dose

(A) Lung bacteria for the LD50 of each clinical isolate. (B) Lung bacteria for the high
dose of each clinical isolate as well as the lab strain A66.1. (C) Blood bacteria for the
LD50 of each clinical isolate. (D) Blood bacteria for the high dose of each clinical isolate
as well as the lab strain A66.1 (*P 0.05, **P0.01).
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Figure 3-3.

Flow Cytometry Gating Scheme

Flow cytometry gating scheme for immune cells. Cells were gated on a forward scatter
(FSC-A) and side scatter (SSC-A), singlets were then gated, and lastly living cells using a
zombie violet viability dye. Neutrophils (Ly6Ghi) were excluded, followed by
macrophages (Ly6GnegCD11chiF4/80hi), more specific alveolar macrophages
(CD11chiF4/80hiCD11b-), and inflammatory macrophages (CD11chiF4/80hiCD11b+), CD4
T Cells (CD3+CD8-CD4+CD49b-), and CD8 T Cells (CD3+CD8+CD4-CD49b-).
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at either time point (Figure 3-4A-B). The alveolar macrophage (AM) populations did not
change over time with the LD50 for any of the clinical isolates besides P310795, which
increased over time. The high dose of clinical isolates as well as the lab strain A66.1 had
decreasing AM populations except for patient isolate P110585 which still maintained the
AMs over time similar to the LD50 (Figure 3-4C-D). The inflammatory macrophage
(iM) population did not have any significant changes over time with the LD50 for any of
the clinical isolates but did trend slightly upwards. The high dose of clinical isolates did
have significant increases in the iM population for P110585 and P210828 with significant
differences seen at time points between strains as well. Clinical isolate P310795 did not
have significant differences between time points but did have differences between doses
with the high dose having significantly more iM cells at both time points (Figure
3-4E-F). Although not significant, there was a negative correlation between number of
neutrophils per lung and lung bacteria burdens for high dose strains P110585 and A66.1
(P = 0.9651, r = -0.01876 and P = 0.9114, r = -0.04268). There was a positive correlation
between number of neutrophils per lung and lung bacteria burdens for high dose strains
P210828 and P310795, with P210828 had a significant positive correlation (P = 0.0472,
r = 0.6483 and P = 0.6212, r = 0.1768). Comparing the high dose for all strains with the
alveolar macrophages seen per lung, though not significant there was a slight positive
correlation seen with strains P110585 and A66.1 (P = 0.8991, r = 0.04961and P = 0.9604,
r = 0.01813), and there was also a positive correlation seen with strains P210828 and
P310795 (P = 0.3996, r = 0.3000 and P = 0.7428, r = 0.1193). The inflammatory
macrophage cells per lung and high dose bacterial burden for strains P110585 and A66.1
were not significantly positively correlated (P = 0.3577, r = 0.3487 and P = 0.6192,
r = 0.1798), and strains P210828 and P310795 were not significantly negatively
correlated with the number inflammatory macrophages per lung (P = 0.5903, r = -0.1945
and P = 0.1936, r = -0.4485).

Capsule Quantification
Because the polysaccharide capsule of S. pneumoniae plays such a vital role in
evasion of the host immune system as well as virulence, the capsule of each clinical
isolate, as well as the lab strain A66.1, was quantified using an ELISA. To determine the
growth curve of each isolate, each strain was grown in a nutrient-rich media and the
OD620 was measured over time. The lab strain A66.1 reached its exponential phase faster
than the clinical isolates with P110585 being the slowest to reach the exponential phase
(Figure 3-5A). The bacterial strains were grown to the determined OD620 from the
previous growth curve (Figure 3-5B) that would allow for 1e6 CFU to be plated per well
in a 96 well plate. The bacterial stocks grown in nutrient-rich media were diluted out and
a back titer was performed to make sure there was 1e6 CFU plated per well on each plate.
The bacteria were coated with blocking buffer, serially diluted anti-capsule type 3 rabbit
serum, anti-rabbit IgG, and yellow ELISA substrate. The plates were then read at OD405.
Strains P110585 and the lab strain A66.1 both contain more capsular polysaccharides
than strains P210828 and P310795 (Figure 3-5C). The increase in the optical density
corresponded to the increase in the capsule that was present over a serum concentration.
At each serum concentration, each strain can be compared to another. More replicates
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Figure 3-4.

Host Immune Cell Populations Differ Between Strains

(A) Clinical isolate LD50 neutrophil populations at 24 and 48 hours p.i. P110585 versus
P210828 at 24 hours (*P=0.031746) (B) Clinical isolate and lab strain A66.1 high dose
neutrophil populations at 24 and 48 hours p.i. P210828 versus P110585 at 24 hours
(P=0.007937) and 48 hours (P=0.015873), A66.1 versus P110585 at 24 hours
(P=0.007937) (C) Clinical isolate LD50 alveolar macrophage populations at 24 and 48
hours p.i. P310795 versus P210828 at 24 hours (P=0.007937) and 48 hours (P=0.031746)
(D) Clinical isolate and lab strain A66.1 high dose alveolar macrophage populations at 24
and 48 hours p.i. P110585 versus P210828 at 48 hours (P=0.007937), P110585 versus
P310795 at 24 hours and 48 hours (P=0.015873), P110585 versus A66.1 at 24 hours
(P=0.039683) and 48 hours (P=0.007937), P210828 versus P310795 at 24 hours
(P=0.007937), P310795 versus A66.1 at 24 hours (P=0.039683) (E) Clinical isolate LD50
inflammatory macrophage populations at 24 and 48 hours p.i. P110585 versus P210828
at 24 hours (P=0.023810), P210828 versus P310795 at 24 hours (P=0.015873) (F)
Clinical isolate and lab strain A66.1 high dose alveolar macrophage populations at 24 and
48 hours p.i. P110585 versus P310795 at 24 hours (P=0.015873) and 48 hours
(P=0.007937), P110585 versus A66.1 at 48 hours (P=0.031746), P210828 versus
P310795 at 48 hours (P=0.007937), P210828 versus A66.1 at 48 hours (P=0.007937).
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Figure 3-5.

Quantification of the Polysaccharide Capsule for All Strains

(A) Growth curve of all clinical isolates and lab strain A66.1 at OD620 versus time (min).
(B) OD620 versus bacterial CFU of all clinical isolates and lab strain A66.1 (C) The serum
concentration versus OD405 of the plated clinical isolates and lab strain A66.1. Increasing
OD corresponds to the amount of polysaccharide capsule present for each isolate.

need to be performed to calculate if there is a significant difference between the capsule
production of each strain.
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CHAPTER 4.

DISCUSSION

The goal of this project was to observe any differences that may be present
between different strains of the same serotype of Streptococcus pneumoniae clinical
isolates. This began by determining the dosage dynamics for each of the strains through
survival studies. The initial results showed that the clinical isolate P110585 was more
infectious than the other two isolates and required a lower infectious dose to be lethal.
The lethal dose, 50% was determined to be 1e3 CFU with a uniformly lethal dose being
1e4 CFU (Figure 3-1A). This difference in lethality between the strains leads to
questions of why there is a difference between the strains when they are all the same
serotype. To begin figuring out what these differences may be, the blood and lung supes
of infected Balb/c mice were plated on blood agar to determine the bacterial burden of
each strain. The bacterial burdens in the lungs were not significantly different between
strains at either dose but grew to higher titers with the high dose for isolates P210828 and
P310795 (Figure 3-2A-B). The higher titers correspond with an influx of neutrophils as
well as a depletion of alveolar macrophages in the lungs of mice that had been infected
with P210828, P310795, and lab strain A66.1 (Figure 3-4).
In the lungs, the first line of defense for the host is the alveolar macrophages that
are resident phagocytes and aid in the clearance of any foreign organisms that the host
may encounter. Upon the clearance of the bacteria, there is alveolar macrophage
depletion or dysfunction/apoptosis [15,16]. This depletion/dysfunction and apoptosis of
the alveolar macrophages can be seen with each of these bacterial infections and differ
between the strains at the high dose (Figure 3-4D). When the bacterial infection cannot
be controlled, the alveolar macrophages have the ability to not only phagocytose the
bacterial cells but also to recruit PMN cells to the infection site. These PMN cells include
neutrophils which assist with the inflammatory environment to aid in the clearance of the
bacteria as well as phagocytosing the bacteria cells [17]. Another cell found at the site of
an infection is the inflammatory macrophage which can begin inflammation in the lung
as well as sustain it and recruit other inflammatory cells [18]. The increase in
inflammatory macrophages in the lung is also seen with the higher doses of clinical
isolates as compared to the LD50 of each isolate at both time points (Figure 3-4E-F).
When looking at the blood bacteria of the infected mice clinical isolate P110585
and lab strain A66.1 both have high titers of bacteria in the blood by 48 hours and even
the LD50 of P110585 has high titers of bacteria in the blood at 48 hours (Figure 3-2C-D).
This could be partly due to the amount of capsule each strain contains. As previously
discussed, the polysaccharide capsule found on the outside of most pneumococcal
serotypes aids in the virulence of the bacterium by helping to evade the host’s immune
system, and the ability of type 3 pneumococcus to shed its capsule can then allow for
further infection leading to invasive pneumococcal disease (IPD). It has been shown that
pneumococcal strains with greater amounts of capsular polysaccharides are more virulent
and are associated more with invasive disease, whereas strains with less capsular
polysaccharides allow for more epithelial adherence and are associated more with lower
respiratory tract infections [19]. The results from the polysaccharide capsule
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quantification experiment correspond with these data because the clinical isolate P110585
and lab strain A66.1 both contained more capsule than the other two clinical isolates and
these two strains were able to invade the blood more frequently and at higher titers than
the other two strains (Figure 3-5C) (Figure 3-2D). The amount of capsule each isolate
produced should be repeated in the future to determine if there is a significant difference
is between the pneumococcal isolates. Taken all together the bacterial burdens, host
innate immune responses, and capsule production for each pneumococcal type 3 strain
can differ and cause different disease outcomes and lethality. Patient isolate P110585 was
more similar to the lab strain A66.1 in all aspects from lung immunological response to
capsule production and patient isolates P210828 and P310795 were more similar.
Streptococcus pneumoniae serotype 3 is part of the clonal class 180 (CC180) and
recently has been shown to contain several distinct lineages. CC180 can be divided into
Clade I-α, Clade I-β, and Clade II. Clade II has become prevalent in North America and
is associated with increased antibiotic resistance [21]. This could be an explanation for
why these type 3 clinical isolates behave differently. Some questions that arise from
these results are: did the environment these strains were isolated from play a major role in
these differences? Does the factor of coinfection with a virus aid in the virulence or
structure of the different strains? Future studies to continue to observe and try to
understand what these differences are and how to address them could be comparing the
genetic sequences of each. Are there mutations that could lead to increased lethality? Are
these isolates in different clades? Understanding more about these clinical isolates would
further the field of clinical medicine as well as vaccine development.
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